Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Intangibles (2023 - 2025)

Historic Intangibles for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $2.1 million.

  • Zhengye Biotechnology Holding's Intangibles changed N/A to $2.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2024, which is 7724.22% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Intangibles stood at $2.1 million for Q2 2025.
  • Zhengye Biotechnology Holding's Intangibles' 5-year high stood at $8.9 million during Q4 2023, with a 5-year trough of $2.1 million in Q4 2024.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Intangibles value was $2.1 million (recorded in 2025), while the average stood at $4.4 million.
  • Examining YoY changes over the last 5 years, Zhengye Biotechnology Holding's Intangibles showed a top increase of 7680.62% in 2024 and a maximum decrease of 7680.62% in 2024.
  • Over the past 3 years, Zhengye Biotechnology Holding's Intangibles (Quarter) stood at $8.9 million in 2023, then tumbled by 76.81% to $2.1 million in 2024, then grew by 2.77% to $2.1 million in 2025.
  • Its Intangibles stands at $2.1 million for Q2 2025, versus $2.1 million for Q4 2024 and $8.9 million for Q4 2023.